Dx-ing Dx investing

Despite decisions by firms like Atlas Venture and Mohr Davidow to exit the early stage diagnostic space, other VCs believe the evolution of underlying technologies and the long-term need to control healthcare costs make it an ideal time to invest.

In a pair of blog posts last month, Atlas' Bruce Booth painted a pessimistic picture of the outlook for venture investing in diagnostics...